What's Happening?
Gilead Sciences, Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the marketing authorization of Trodelvy in combination with Keytruda for treating adult patients with unresectable
locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1. This recommendation is based on the Phase 3 ASCENT-04/KEYNOTE-D19 study, which showed a significant reduction in the risk of disease progression or death when using Trodelvy plus Keytruda compared to standard chemotherapy plus Keytruda. The European Commission's decision on this indication is expected later in 2026.
Why It's Important?
The recommendation by CHMP is significant as metastatic TNBC is an aggressive form of breast cancer with limited treatment options and poor prognosis. Approximately 40% of metastatic TNBC tumors are PD-L1 positive, making them more aggressive and associated with shorter survival. The approval of Trodelvy plus Keytruda could provide a new first-line treatment option, potentially improving outcomes for patients with this challenging cancer type. This development underscores Gilead's commitment to advancing cancer treatment and could establish Trodelvy as a backbone therapy for TNBC across PD-L1 status.
What's Next?
The European Commission is expected to make a decision on the marketing authorization later in 2026. If approved, Trodelvy plus Keytruda could become a standard first-line treatment for PD-L1 positive metastatic TNBC in Europe. This could lead to broader adoption of the therapy and potentially influence treatment guidelines globally. Gilead is also continuing to evaluate Trodelvy in multiple ongoing Phase 3 trials across various tumor types, which could further expand its use in oncology.
